Mesenchymal stem cells and uses therefor

Patent metadata

Field	Value
Publication number	US-9694035-B2
Application number	US-201414334128-A
Country	US
Kind code	B2
Filing date	Jul 17, 2014
Priority date	Mar 22, 2004
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

First claim

The invention claimed is:

1. A method of reducing inflammation in the gastrointestinal tract of a patient in need thereof, comprising the step of intravenously or intraarterially administering to a human suffering from inflammation of the gastrointestinal tract a suspension of cells in an amount effective to reduce the inflammation, wherein the cells are genetically unmodified allogeneic mesenchymal stem cells, wherein the suspension of mesenchymal stem cells is at least 95% homogeneous and wherein the mesenchymal stem cells express CD73 and CD105.

2. The method of claim 1 , wherein the patient suffers from Crohn's disease, inflammatory bowel disease, gastrointestinal graft-versus-host disease (GVHD), or autoimmune gastritis.

3. The method of claim 2 , wherein the patient suffers from gastrointestinal graft-versus-host disease.

4. The method of claim 3 , wherein the patient was refractory to one or more treatments to GVHD.

5. The method of claim 1 , wherein the suspension further comprises an acceptable pharmaceutical carrier.

6. The method of claim 5 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection.

7. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 5 cells/kg to about 1×10 7 cells/kg.

8. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 6 cells/kg to about 5×10 6 cells/kg.

9. The method of claim 1 , wherein the suspension is administered in an amount of about 3×10 6 cells/kg.

10. The method of claim 1 , wherein the method comprises increasing production or secretion of an anti-inflammatory cytokines interleukin-4 or interleukin-10.

11. The method of claim 1 , wherein the method comprises reducing production or secretion of a pro-inflammatory cytokine in a human in need thereof.

12. The method of claim 2 , wherein the patient suffers from inflammatory bowel disease.

13. The method of claim 11 , wherein the pro-inflammatory cytokine that is reduced in production or secretion is selected from the group consisting of interferon-γ, TNF-α, and IL-17.

Assignees

• Mesoblast Int Sárl
• Mesoblast Int Sarl

Inventors

• Aggarwal Sudeepta
• Pittenger Mark F
• Varney Timothy

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P7/06

  Antianaemics · CPC title